IDEAYA Biosciences Enters Clinical Collaboration With Roche's Genentech To Evaluate The Efficacy And Safety Of IDE892, Its Investigational MTA-Cooperative PRMT5 Inhibitor, In Combination With GDC-7035, Genentech's KRAS G12D Inhibitor, In Patients With Pancreatic Ductal Adenocarcinoma

William Blair Initiates Coverage On IDEAYA Biosciences with Outperform Rating

William Blair analyst Alethia Young initiates coverage on IDEAYA Biosciences (NASDAQ:IDYA) with a Outperform rating.

Guggenheim Maintains Buy on IDEAYA Biosciences, Raises Price Target to $57

IDEAYA Biosciences Announced First Patient Has Been Dosed In The OptimUM-11 Phase 3 Registrational Trial Evaluating Darovasertib In Combination With Crizotinib For Patients With Primary Uveal Melanoma

Global Phase 3 registrational trial evaluating darovasertib, a first-in-class oral protein kinase C (PKC) inhibitor, in combination with crizotinib, an oral cMET inhibitor, as adjuvant therapy for patients with primary

2 Under-the-Radar Stocks to Buy and Hold

The article recommends two underrated biotech stocks: Axsome Therapeutics, which is experiencing strong growth with its drug Auvelity (51% YoY sales growth) and has a promising pipeline including potential new indications; and Exelixis, a cancer-focused biotech with a dominant drug Cabometyx protected until at least 2030, plus encouraging progress on pipeline candidates like zanzalintinib.

Roche Secures FDA Approval for First At-Home Thyroid Eye Disease Therapy

Roche earns FDA approval for Enspryng in thyroid eye disease, offering the only at-home subcutaneous treatment for TED.

FDA approves Roche’s Enspryng, a first-in-class IL-6R inhibitor, as the first and only at-home subcutaneous treatment option for thyroid eye disease (TED)

The FDA has approved Roche's Enspryng (satralizumab) as the first at-home subcutaneous treatment for thyroid eye disease (TED). The approval was based on Phase III SatraGO-1 and -2 studies, with SatraGO-2 demonstrating significant reductions in eye bulging (proptosis) and improvements in double vision (diplopia). Enspryng is an IL-6R inhibitor using novel recycling antibody technology and represents the second indication for the drug, following its 2020 approval for neuromyelitis optica spectrum disorder (NMOSD).